Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myeloid, Acute 48Leukemia, Lymphocytic, Chronic, B-Cell 27Neoplasms 19Lymphoma, Non-Hodgkin 19Recurrence 17Lymphoma, Mantle-Cell 10Lymphoma, Large B-Cell, Diffuse 10Lymphoma, Follicular 9Multiple Myeloma 8Myelodysplastic Syndromes 6Lymphoma 6Lymphoma, B-Cell, Marginal Zone 5Leukemia, Myelomonocytic, Chronic 4Leukemia 4Hematologic Neoplasms 4Chromosome 17 deletion 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Waldenstrom Macroglobulinemia 2Small Cell Lung Carcinoma 2Prostatic Neoplasms 2Lymphoma, T-Cell 2Lymphoma, B-Cell 2Leukemia, Myeloid 2Leukemia, Biphenotypic, Acute 2Carcinoma, Non-Small-Cell Lung 2Tumor Lysis Syndrome 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Philadelphia Chromosome 1

Interventions

venetoclax 1eprenetapopt 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Myeloid Malignancy × venetoclax × Clear all
NCT04214860 2025-03-17

APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies

Aprea Therapeutics

Phase 1 Completed
51 enrolled 9 charts

Myeloid Malignancy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡